Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 817 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR What to Know About Coping With Breast Cancer During Pregnancy: An... November 14, 2023 Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active... October 29, 2025 FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma April 29, 2021 New ESMO Local and Locoregional Prostate Cancer Living Guideline v1.0 February 19, 2026 Load more HOT NEWS Women in science: Cancer research pioneers – part 1 New Treatment Helps Survivors Regain Sensation After Breast Cancer More than 65,000 people are left waiting to find out if... FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR...
